Johnson & Johnson (NYSE:JNJ) Given New $240.00 Price Target at Wolfe Research

Johnson & Johnson (NYSE:JNJ) had its target price boosted by Wolfe Research from $225.00 to $240.00 in a report published on Monday morning,MarketScreener reports. They currently have an outperform rating on the stock.

Other analysts have also issued research reports about the company. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Barclays increased their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 30th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $212.62.

Johnson & Johnson Trading Down 1.5%

NYSE JNJ opened at $204.32 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average of $201.45 and a 200-day moving average of $183.45. The company has a market cap of $492.26 billion, a PE ratio of 19.72, a PEG ratio of 2.13 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s payout ratio is 50.19%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at $26,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson in the second quarter valued at about $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the third quarter worth about $28,000. Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. Finally, GFG Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at about $35,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.